Statistics for Alnylam Pharmaceuticals (id:7139 ALNY)

Valuation metrics

Market cap

31.83B

Enterprise value

32.04B

Trailing P/E (ttm)

-69.48

Forward P/E

-202.30

PEG ratio

-202.30

Price/Sales (ttm)

15.20

Price/Book (mrq)

983.27

Enterprise Value/Revenue

15.29

Enterprise Value/EBITDA

-242.42

Overview

Shares outstanding

128.98M

Float

128.44M

Shares short

3.70M

% Held by insiders

0.00%

% Held by institutions

0.98%

Average volume (10 days)

990.42K

Average volume (90 days)

Price summary

52-Week low

141.98

52-Week high

304.39

52-Week change

35.00%

Beta

0.39

50-Day moving average

273.83

200-Day moving average

211.50

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-15.86%

Operating margin

-15.35%

Operational effectiveness

Return on assets

-2.92%

Return on equity

199.53%

Income statement

Revenue (ttm)

16.52

Revenue per share (ttm)

16.52

Quarterly revenue growth (yoy)

Gross profit (ttm)

1.52B

EBITDA

-132,146,000.00

Net income to common (ttm)

-332,264,000.00

Diluted EPS (ttm)

-2.61

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

2.78B

Total cash per share (mrq)

21.56

Total debt (mrq)

2.73B

Total Debt/Equity (mrq)

8.43K

Current ratio (mrq)

274.90%

Book value per share (mrq)

0.25

Cash flow

Cash flow statement

56.56M

Levered free cash flow (LFCF)

309.57M